QTc Prolongation With Antidepressants and haldol classification Antipsychotics

ABSTRACT: QT prolongation is a rare adverse event associated with many haldol classification drugs, including antipsychotics and antidepressants. The majority of cases have occurred in patients taking an haldol classification offending agent with multiple identifiable risk factors for corrected QT haldol classification (qtc) prolongation. Typical antipsychotics have been implicated in many cases of torsades haldol classification de pointes and qtc prolongation. Most atypical antipsychotics are considered to have a better cardiac haldol classification profile. Tricyclic and tetracyclic antidepressants and selective serotonin reuptake inhibitors have haldol classification also been linked to qtc prolongation. Serotonin norepinephrine reuptake inhibitors have a better adverse-event profile. Clinicians should strive to use antipsychotics or antidepressants with a haldol classification lower risk of qtc prolongation in patients with multiple risk haldol classification factors for this adverse event.

Prolongation of the QT interval is a concern for clinicians haldol classification managing psychiatric drug regimens. QT-interval prolongation is estimated to occur in up to 10% of patients taking antiarrhythmic drugs with QT-prolonging potential. 1 this adverse event is estimated to occur less frequently haldol classification with other drugs, such as psychiatric medications. 1 although QT prolongation occurs rarely, it can lead to serious conditions such as torsades de haldol classification pointes (tdp), a serious ventricular arrhythmia that can lead to sudden cardiac haldol classification death. 2 this review will summarize the risk factors for developing haldol classification QT prolongation and the QT-prolonging potential of antipsychotics and antidepressants.

QT prolongation is an extended corrected QT (qtc) interval seen on an ECG at rest. 2 because the QT interval is dependent on heart rate, the qtc interval is calculated to control for this factor. 2 qtc can be calculated by a variety of methods. 3 definitions of qtc prolongation vary, but often this condition is described as a qtc interval haldol classification of >440 ms. 2 other definitions allow for a higher cutoff, such as 460 ms, in females. 3 mechanism

The QT interval represents the summation of cardiac action potentials. 2 drug-induced QT prolongation is thought to be caused by the haldol classification inhibition of the delayed potassium rectifier current ikr (rapid) by specific drugs. 2 ikr is an outward current controlled by potassium channels haldol classification that is responsible, in part, for the repolarization of ventricular myocytes. 2 when a drug interferes with this current, thereby disrupting repolarization, the QT interval is prolonged. 2 clinical significance of qtc prolongation

Nonpsychiatric drugs that are well known for causing qtc prolongation, such as sotalol and dofetilide, extend the qtc interval by 30 to 40 ms. 4 it is agreed that this extension of the interval haldol classification is clinically significant. 4 clinicians continue to debate whether a lower threshold would haldol classification be clinically significant. Drugs causing only a 5- to 10-ms increase have been withdrawn from the market because of haldol classification cardiac concerns, making this lower interval a common definition of drug-induced qtc prolongation. 5 an increase of 5 ms carries a potential increased haldol classification risk of tdp. 4 an increase of >20 ms has a significant increased risk of tdp. 6 for the purposes of this article, the conservative increase of >5 ms is considered clinically significant. Risk factors

The majority of patients who develop drug-induced QT prolongation also have multiple risk factors ( TABLE 1). 1 A study evaluating the frequency of risk factors for haldol classification drug-induced tdp found that two or more identifiable risk factors haldol classification were present in 85% of cases. 7 risk factors included heart disease (90%), age >65 years (72%), female sex (70%), multiple offending drugs (15%), and hypokalemia (13%). 7 females are at higher risk than males since testosterone haldol classification shortens the QT interval. 2 hypokalemia is a risk factor owing to the role haldol classification of the potassium channels in QT prolongation. 2 despite these identifiable risk factors, there is intrapersonal variability in developing QT prolongation. It has been suggested that this is due to differences haldol classification in genetic polymorphisms in ikr channels. 2

The antidepressants and antipsychotics that are correlated with a higher haldol classification risk of QT prolongation are listed in TABLE 2. TABLE 3 includes medications that have been determined to have haldol classification a lower risk. This determination was based on a review of literature and haldol classification data from the comprehensive QT prolongation database, crediblemeds, previously known as the university of arizona center for education haldol classification and research on therapeutics. 8

Typical (first-generation) antipsychotics: the typical antipsychotics associated with the greatest risk of qtc haldol classification prolongation are thioridazine, haloperidol, chlorpromazine, and pimozide. Harrigan and colleagues conducted an open-label, randomized, parallel-group trial of 183 patients with stable psychotic disorders who haldol classification were randomized to six different antipsychotics, including thioridazine 300 mg/day and haloperidol 15 mg/day. 9 thioridazine increased the qtc interval from baseline by 30.1 ms, and haloperidol increased it by 7.1 ms. 9 this is consistent with results of other published reports. 2,3,10 chlorpromazine is considered a high-risk drug for qtc prolongation, with one study finding an increased relative risk of 1.37 (95% CI 1.14-1.64). 11 pimozide, a typical antipsychotic usually reserved for patients unresponsive to standard haldol classification treatment for tourette syndrome, has also been linked to tdp, although well-designed clinical trials are lacking. 8,12

Loxapine is not associated with qtc prolongation, according to a double-blind, placebo-controlled, crossover study in healthy volunteers. 13 fluphenazine, perphenazine, thiothixene, and trifluoperazine have not been evaluated, so conclusions about their qtc-prolongation potential cannot be drawn.

Atypical (second-generation) antipsychotics: the atypical antipsychotics ziprasidone and iloperidone are considered to have haldol classification the potential to cause clinically significant increases in qtc. Two well-designed qtc trials demonstrated that ziprasidone caused a qtc increase haldol classification of 15.9 ms and 9.6 ms, respectively. 9,14 despite these findings, a post hoc analysis of phase II–IV trials involving 4,306 subjects taking ziprasidone revealed a mean change in qtc haldol classification of only 3.6 ms. 15 in a thorough qtc trial, iloperidone was studied at therapeutic and supratherapeutic doses in stable haldol classification patients who were diagnosed with schizophrenia or schizoaffective disorder. 14 iloperidone 8 mg twice daily increased qtc by an haldol classification average of 8.5 ms, 12 mg twice daily increased it by 9.0 ms, and 24 mg daily increased it by 15.4 ms. 14 these results are similar to those from other trials haldol classification of iloperidone. 14,16 overall, caution should be exercised with use of iloperidone and ziprasidone.

Quetiapine has had several mixed reports regarding its ability to haldol classification prolong the qtc interval. Studies indicate changes in qtc intervals from –12.2 ms to 8 ms. 9,10,14,17,18 A review of 12 published case reports of quetiapine-related qtc prolongation concluded that all 12 patients had at haldol classification least one identifiable risk factor for qtc prolongation. 10 large-scale, thorough qtc trials are needed to clarify the prolongation risk haldol classification of quetiapine.

Other atypical antipsychotics are considered to have a lower potential haldol classification to increase qtc. In the trial by harrigan and colleagues, both risperidone and olanzapine had clinically insignificant increases in qtc haldol classification (3.6 ms and 1.7 ms, respectively). 9 these findings are consistent with those of other trials. 9,19,20 active-control studies investigating paliperidone and asenapine also found clinically insignificant haldol classification increases. 17,18 several studies, including a meta-analysis comparing atypical antipsychotics, concluded that aripiprazole is not associated with increases in qtc haldol classification interval. 21,22 clozapine has been linked to tdp in case reports, but it is typically not considered to extend the qtc haldol classification interval. 3 the two newer atypical antipsychotics, brexpiprazole and lurasidone, have limited data but have not been shown to have haldol classification significant effects on qtc interval. 23 except for ziprasidone, iloperidone, and possibly quetiapine, atypical antipsychotics are considered to have a relatively benign effect haldol classification on qtc interval.

Selective serotonin reuptake inhibitors (ssris): there are published case reports linking all six currently available haldol classification ssris (fluvoxamine, fluoxetine, paroxetine, sertraline, citalopram, and escitalopram) to qtc prolongation. 5 according to a recent meta-analysis of 16 articles representing all six currently available ssris, the ssris as a drug class may increase qtc by haldol classification 6.10 ms compared with placebo (95% CI 3.47-8.73). 5 citalopram (10.58 ms), escitalopram (7.27 ms), and sertraline (3.00 ms) caused significant increases in qtc intervals, whereas fluoxetine, paroxetine, and fluvoxamine were not associated with a significant increase compared haldol classification with placebo. The 3-ms increase by sertraline was not considered a clinically significant haldol classification finding. The results of this meta-analysis are consistent with other findings. 4 in addition to causing the largest change in qtc haldol classification interval of all the ssris, citalopram has been linked to numerous episodes of tdp, and dosing limits have been imposed by the FDA. 5,7 clinicians should routinely monitor for qtc prolongation when citalopram haldol classification and escitalopram are used at high doses or in patients haldol classification with identifiable risk factors.

Tricyclic antidepressants (tcas) and tetracyclic antidepressants (tecas): tcas are associated with prolongations in qtc intervals. A prospective cohort study in the netherlands demonstrated statistically significant haldol classification increases for amitriptyline (5.1 ms), imipramine (12.8 ms), maprotiline (13.9 ms), and nortriptyline (23.3 ms). 24 these findings are consistent with those of other prospective haldol classification studies. 5,11 desipramine, clomipramine, and trimipramine are all considered to confer a possible risk haldol classification of tdp. 8 doxepin is not associated with a clinically significant increase haldol classification in qtc interval, with one study demonstrating a small increase (2.38 ms). 25

Serotonin norepinephrine reuptake inhibitors (snris): with the exception of venlafaxine, snris are not associated with increased qtc intervals. The majority of studies have not shown a statistically significant haldol classification increase in qtc interval with therapeutic doses of venlafaxine; however, there is some concern based on published case reports. 6 venlafaxine should be used with caution in patients with haldol classification risk factors for qtc prolongation. In clinical trials, levomilnacipran, milnacipran, desvenlafaxine, and duloxetine have not demonstrated increases in qtc. 6,26

Other antidepressants: bupropion, trazodone, vilazodone, and vortioxetine are not associated with clinically significant increases in haldol classification qtc intervals at therapeutic doses. 6,8,27 in some resources, mirtazapine is listed as a QT-prolonging drug; however, the evidence behind these claims has been debated. 6,8 case reports from the manufacturer and a pharmacoepidemiologic study haldol classification show the potential for mirtazapine to extend the qtc interval. 6 however, results of an ECG safety analysis and two toxicology studies haldol classification did not find qtc prolongation with mirtazapine, even in overdose. 6 higher-quality studies are needed to further explore the relationship between haldol classification mirtazapine and qtc prolongation; however, bupropion, vilazodone, and vortioxetine are considered to have minimal potential to increase haldol classification qtc. Recommendations

3. If a drug with higher potential ( TABLE 3) is necessary and an alternative cannot be used, monitoring is recommended. Consider obtaining an ECG and serum potassium levels following initiation haldol classification of the drug. 1 clinicians should consult individual package inserts for drug-specific manufacturer recommendations.

Almost all antidepressants and antipsychotics have been linked to QT haldol classification prolongation. This effect is thought to occur when specific drugs interfere haldol classification with cardiac potassium channels and repolarization. It has been shown that the majority of patients who haldol classification experience QT prolongation have multiple identifiable risk factors. 1 the typical antipsychotics thioridazine and haloperidol have the strongest haldol classification evidence linking their use to QT prolongation and tdp. Common medications that are considered to have a high risk haldol classification are the ssris citalopram and escitalopram. New studies on this topic are expected to emerge owing haldol classification to the FDA’s requirement to investigate the cardiac profiles of medications. REFERENCES

1. Zipes DP, camm AJ, borggrefe M, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias haldol classification and the prevention of sudden cardiac death: a report of the american college of cardiology/american heart association task force and the european society of haldol classification cardiology committee for practice guidelines (writing committee to develop guidelines for management of patients with haldol classification ventricular arrhythmias and the prevention of sudden cardiac death): developed in collaboration with the european heart rhythm association and haldol classification the heart rhythm society. Circulation. 2006;114:e385-e484.

17. Hough DW, natarajan J, vandebosch A, et al. Evaluation of the effect of paliperidone extended release and quetiapine haldol classification on corrected QT intervals: a randomized, double-blind, placebo-controlled study. Int clin psychopharmacol. 2011;26:25-34.